Latest news with #sequencing
Zawya
31-07-2025
- Health
- Zawya
Africa Centres for Disease Control and Prevention (Africa CDC) and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa
The Africa Centres for Disease Control and Prevention (Africa CDC) and the European Commission today announced the launch of the Partnership to Accelerate Mpox Testing and Sequencing in Africa (PAMTA), a landmark initiative to boost diagnostics and outbreak response capabilities in Mpox-affected African countries. Co-funded under the EU4Health 2024 Work Programme, PAMTA reflects the growing momentum of Africa–EU health cooperation and aims to reinforce the continent's resilience against current and future health threats. The initiative will accelerate testing, sequencing, capacity building, and local manufacturing efforts for mpox and other priority pathogens across Africa through a €9.4 million to Africa CDC and the African Society for Laboratory Medicine (ASLM), managed by the European Health and Digital Executive Agency (HaDEA). The project officially began on 1 June 2025 and will be implemented over three years. Africa CDC Director General, H.E. Dr Jean Kaseya, welcomed the initiative as a timely and strategic intervention to close the diagnostic gap for Mpox and other outbreaks in Africa. 'This partnership reflects our commitment to working with trusted partners to build agile and self-reliant public health systems across Africa. Together with the EU and our technical partners, we are setting a new benchmark for outbreak detection and response.' The PAMTA initiative focuses on four key objectives: scaling up Mpox testing with the goal of supporting over 150,000 tests across the continent; strengthening genomic sequencing capacity to track viral evolution and spread; building human resource capacity in molecular diagnostics, genomics, bioinformatics and data interpretation; and promoting the production and validation of locally developed testing kits within Africa. 'PAMTA marks a historic milestone as the first initiative jointly signed between the European Commission and Africa CDC,' said Deputy Head of DG HERA, Laurent Muschel. 'Building on HERA's earlier donation of Mpox vaccines, this action enables a critical next step: strengthening diagnostic capacities as part of a broader medical countermeasures approach. It reflects our shared commitment to reinforcing epidemic preparedness across Africa — from vaccines to diagnostics, from innovation to manufacturing. This action shows that, together, the African Union and the European Union can deliver tangible results to protect lives.' The launch of PAMTA builds on broader efforts by the EU and its partners to address the Mpox outbreak. By mid-2025, more than 600,000 vaccine doses had been delivered to African countries through HERA and Team Europe. Simultaneously, research initiatives such as MPX-RESPONSE and EDCTP3 continue to explore new therapeutic options, while the Africa Pathogen Genomics Initiative (PGI)—also funded through EU4Health—is enhancing public health laboratory networks and genomic surveillance across the continent through public private partnerships. PAMTA marks a significant milestone in EU–Africa collaboration for health resilience. By supporting comprehensive diagnostics and fostering local innovation, the initiative is helping to lay a strong foundation for Africa's long-term pandemic preparedness and response capabilities. Distributed by APO Group on behalf of Africa Centres for Disease Control and Prevention (Africa CDC).
Yahoo
21-07-2025
- Business
- Yahoo
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025
MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at Date: Thursday, August 7, 2025, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the 'PacBio Q2 Earnings Call.'About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Contacts Investors: Todd Friedmanir@ Media:pr@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Metagenomics Market Advancing with Microbiome Research Breakthroughs and Expanding Applications in Healthcare and Agriculture, 2025-2032
According to a recent report by Coherent Market Insights, the global Metagenomics Market is estimated to be valued at USD 2.36 Bn in 2025 and is expected to reach USD 4.13 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032. The growing use of metagenomics across diverse industries such as healthcare and biotechnology is expected to drive market growth. Metagenomics offers a wide range of applications, including gene identification for disease treatment, microbiome analysis, biofuel production, and environmental cleanup. Additionally, advancements in sequencing technologies and declining sequencing costs are projected to support the expansion of the metagenomics sector. Increasing global research efforts in this field are also anticipated to further boost market growth during the forecast period. Request a Sample Copy of this Report at: Global Metagenomics Market Key Takeaways According to Coherent Market Insights (CMI), the global metagenomics market size is estimated to reach USD 2.36 Bn in 2025 and USD 4.13 Bn by 2032, registering a CAGR of 8.3%. Based on product, reagents & consumables segment is expected to dominate the industry, accounting for a revenue of about USD 1.30 Bn in 2025. By technology, shotgun sequencing segment is set to account for more than two-fifths of the global metagenomics market share in 2025. Based on application, drug discovery segment is likely to hold a market share of 52.8% in 2025 As per Coherent Market Insights' latest metagenomics market analysis, North America is expected to retain its dominance, accounting for 38% of the global market share in 2025. Asia Pacific metagenomics market is poised to experience fastest growth during the assessment period. Rising Prevalence of Chronic and Infectious Diseases Fueling Market Growth A new report by Coherent Market Insights outlines prominent metagenomics market growth factors. One such growth driver is the increasing incidence of chronic and infectious diseases worldwide. Rise in chronic and infectious diseases necessitates rapid and accurate identification of pathogens, including rare and complex microbial infections. This is where metagenomics steps in. Metagenomics offers a powerful tool for identifying novel pathogens as well as analyzing disease-related microbiomes. Thus, rising prevalence of chronic and infectious diseases, coupled with growing demand for enhanced diagnostics technologies, is expected to boost growth of metagenomics market during the forecast period. Purchase Now Up to 25% Discount on This Premium Report @ High Cost of Sequencing Technologies Restraining Market Growth The future metagenomics market outlook looks bright. However, high cost of advanced metagenomic sequencing instruments poses a barrier to widespread market expansion. Sequencing platforms required for advanced metagenomic analysis are quite expensive. This limits their adoption, especially across low- and middle-income regions, thereby reducing overall metagenomics market demand. Advancements in Genomic Technologies Opening New Growth Opportunities Ongoing innovations in next-generation sequencing (NGS), shotgun metagenomics, and bioinformatics tools are making metagenomics studies faster as well as more accurate and cost-effective. These technological advancements are expected to unlock new growth opportunities for metagenomics companies during the forecast period. Impact of AI on the Metagenomics Market Artificial Intelligence (AI) is emerging as a powerful tool in the metagenomics market. It has the potential to enhance data analysis, pattern recognition, and predictive modeling. AI tools speed up and improve the analysis of complex microbial data. They help identify new microorganisms, gene functions, and disease links more precisely. This accelerates the discovery of therapeutic targets, environmental monitoring, and microbiome research. Leading players like Thermo Fisher Scientific and Illumina are increasing this AI trend. For instance, in 2025, Thermo Fisher Scientific launched a new AI-enhanced metagenomics data analytics platform aimed at improving accuracy and speed of microbial classification. Emerging Metagenomics Market Trends Growing demand for precision medicine is a key growth-shaping trend in the market. Metagenomics provides insights into the microbiome's role in health and diseases, thereby enabling the development of targeted therapies. Many nations are increasingly investing in microbiome research projects like the Human Microbiome Project. This will further boost metagenomics market growth during the forecast period. Expanding applications in environmental and agricultural microbiology are expected to play a key role in boosting the metagenomics market value. Metagenomics is being widely used to assess microbial diversity in water, soil, and waste treatment systems. There is also a growing trend of using AI and ML for analyzing vast metagenomic datasets. Such innovations are expected to create lucrative opportunities for metagenomic product manufacturers. Analyst's View ' The global metagenomics industry is expected to experience rapid growth, owing to rising incidence of chronic and infectious diseases, expanding usage of metagenomics in drug discovery, and advancements in genomic technologies,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Metagenomics Market Event Description and Impact Post-Pandemic Acceleration of Genome Research Funding Description: Global research funding for microbiome studies is increasing, with emphasis on infectious disease surveillance and pandemic preparedness. Impact: This drives demand for clinical-grade metagenomic platforms for rapid pathogen detection and variant tracking. AI & Deep Learning Revolution in Microbiome Analysis Description: LLMs and AI tools are now being used for microbial functional annotation and strain-level resolution. Impact: These technologies improve the speed and accuracy of interpreting complex metagenomic datasets, enhancing applications across clinical diagnostics, environmental monitoring, and agriculture. Strategic M&A Activity Description: In May 2025, Mapmygenome (India) acquired Canadian CRO Microbiome Insights to scale up global sequencing operations. Impact: Such strategic mergers and acquisitions strengthen international presence and diversify service portfolios, fostering market consolidation in the metagenomics sector. Competitor Insights Key companies listed in metagenomics market report: - Illumina, Inc. - Bio-Rad Laboratories, Inc. - QIAGEN - PerkinElmer, Inc. - Novogene Co., Ltd. - Thermo Fisher Scientific, Inc. - Promega Corporation - Oxford Nanopore Technologies - Takara Bio, Inc. - PacBio - F. Hoffmann-La Roche Ltd Key Developments In April 2025, Metabolon introduced the Microbiome Research Solution for high-quality metagenomics and metabolomics data. It combines novel microbiome panel, metagenomics sequencing, and multiomics bioinformatics tools to create the industry's most powerful microbiome research toolkit. In July 2024, MGI Tech launched Human Microbiome Metagenomics Sequencing Package. This comprehensive solution encompasses the full workflow of human microbiome metagenomics sequencing, from sample collection and extraction to library preparation, sequencing, and analysis. The package features high automation and flexible throughput. Market Segmentation Product Insights (Revenue, USD Bn, 2020 - 2032) Reagents & Consumables Instruments Sequencing & Data Analytics Services Technology Insights (Revenue, USD Bn, 2020 - 2032) Shotgun Sequencing 16S Sequencing Whole Genome Sequencing Others Application Insights (Revenue, USD Bn, 2020 - 2032) Drug Discovery Clinical Diagnostics Others End User Insights (Revenue, USD Bn, 2020 - 2032) Pharmaceutical Companies Research Laboratories Others Regional Insights (Revenue, USD Bn, 2020 - 2032) North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Yahoo
26-06-2025
- Business
- Yahoo
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform has been selected to support Regeneron Genetics Center® (RGC™) and its recently launched U.S. large-scale proteomics study. The study, comprised of 200,000 blood serum samples secured by RGC from its long-standing research collaboration with Geisinger Health System, will be combined with the recently announced UK Biobank Pharma Proteomics Project, the largest proteomics study undertaken to date, which will also utilize Ultima's UG 100 sequencing platform for the analysis of 600,000 samples from UK consented participants. Combined, these studies reflect the growing role of high-throughput, cost-efficient sequencing in enabling large-scale counting applications across proteomics and other emerging omics fields. For these efforts, RGC will utilize the Olink Explore HT platform and Ultima's UG 100 platform. Ultima's technology was selected for its scalability, efficiency, and suitability for large population-level studies requiring high-throughput data generation. "We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights," said Gilad Almogy, founder and CEO of Ultima Genomics. "These RGC proteomics studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform." About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Ultima Media ContactVikki Herrera408-206-7009vikki@ View original content to download multimedia: SOURCE Ultima Genomics
Yahoo
23-06-2025
- Business
- Yahoo
Canaccord Raises Price Target Of Illumina, Inc. (ILMN).
Illumina, Inc. (NASDAQ:ILMN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Kyle Mikson, an analyst at Canaccord Genuity, increased his price objective for Illumina, Inc. (NASDAQ:ILMN) shares from $87 to $99 on June 11 while keeping his rating at Hold. A research facility with medical professionals surrounded by diagnostic equipment. The announcement comes after Illumina, Inc. (NASDAQ:ILMN) CEO Jacob Thaysen stated in a podcast that when pricing pressures lessen, revenue improvements may be driven by robust volume growth from clinical customers. Thaysen stated that its long-term development plan is still in place, provided that the NovaSeq X sequencing system is adopted more widely. Canaccord is still on the sidelines even if there are indications that its performance will improve in the medium term. The recent performance of Illumina, Inc. (NASDAQ:ILMN), a significant participant in sequencing and genomics technology, has been hampered by pricing challenges. CEO Jacob Thaysen highlighted the need for clinical volume increase in promoting both future revenue growth and recovery. The implementation of the NovaSeq X platform will be essential to carrying out Illumina, Inc. (NASDAQ:ILMN)'s expansion goal. Canaccord's raised target reflects cautious optimism about improving execution while remaining neutral overall. While we acknowledge the potential of ILMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
